On July 25, 2023, Kelly Wilson, Chief Executive Officer and Chief Operating Officer of Immune Therapeutics, Inc., delivered a letter of resignation to the Company, pursuant to which Ms. Wilson resigned as Chief Executive Officer of the Company, effective immediately. Ms. Wilson?s resignation was not the result of any material dispute or disagreement on any matter relating to the operations, policies or practices of the Company. On July 25, 2023, the Board of the Company appointed Noreen Griffin as Chief Executive Officer.

Ms. Griffin, age 70, served as the Vice President of the Company from November 2022 to July 2023. Since November 2012, Ms. Griffin has also served as Manager of TNI Biotech International Ltd., a subsidiary of the Company. Since January 2021, Ms. Griffin has also been a director and Chief Executive Officer of Forte Animal Health Inc. From March 2012 to September 2019, Ms. Griffin, a co-founder of the Company, was Chief Executive Officer and a director of the Company.

From April 2020 to September 2020, Ms. Griffin was Chief Executive Officer and President, respectively, of Cytocom, Inc. prior to its merger with Cleveland BioLabs, Inc., now known as Statera Biopharma, Inc. (OTC Expert Market: STAB), a clinical-stage biopharmaceutical company and former subsidiary of the Company. From September 2020 to April 2022, Ms. Griffin was Vice President of Business Development at Statera Biopharma, Inc. Ms. Griffin attended North Florida Community College from 1978 to 1980 and left prior to graduation in order to pursue full-time employment opportunities.